AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15150632 — intervention group
Group type: COMPARATOR
Intervention: Brushing (B) side
Number of subjects: 12
Study 15150632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of SUL, GI, and BOP scores
Number of subjects: 12
Study 11799544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy and physician advice
Number of subjects: 381
Study 9730426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 82
Study 9730426 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 82
Study 9730426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus with antithymocyte globulin
Number of subjects: 82
Study 9730426 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine with antithymocyte globulin
Number of subjects: 82
Study 9730426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus without antithymocyte globulin
Number of subjects: 82
Study 9730426 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine without antithymocyte globulin
Number of subjects: 82
Study 7756587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic agents (cyclophosphamide or chlorambucil)
Number of subjects: 228
Study 7756587 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment or corticosteroids (control group)
Number of subjects: 228
Study 2111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen intake of 0.2 g kg body-weight-1 24 h-1
Number of subjects: 39
Study 2111195 — intervention group
Group type: COMPARATOR
Intervention: No nitrogen intake
Number of subjects: 39
Study 2111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen intake of 0.3 g kg body-weight-1 24 h-1
Number of subjects: 39
Study 2111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen intake of 0.1 g kg body-weight-1 24 h-1
Number of subjects: 39
Study 2111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen intake of 0.0 g kg body-weight-1 24 h-1
Number of subjects: 39
Study 761953 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nomifensine
Number of subjects: 9
Study 761953 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg racemic amphetamine
Number of subjects: 9
Study 761953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30964707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (PPARγ agonist)
Number of subjects: 104
Study 30964707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 28793980 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led, social media-delivered safer sex intervention
Number of subjects: 196
Study 28793980 — intervention group
Group type: COMPARATOR
Intervention: Existing online sexual health website (control)
Number of subjects: 196
Study 26061799 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Balance for Kids with Play (EB4K with Play) intervention
Number of subjects: 879
Study 26061799 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Balance for Kids with Play (EB4K with Play) intervention (fourth-grade students)
Number of subjects: 879
Study 26061799 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Balance for Kids with Play (EB4K with Play) intervention (third-grade students)
Number of subjects: 879
Study 26061799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 879
Study 23279750 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based PT program (six 1 h sessions, eight patients per group)
Number of subjects: 376
Study 23279750 — intervention group
Group type: COMPARATOR
Intervention: Usual PT care (two individual visits with a physical therapist)
Number of subjects: 376
Study 20817484 — intervention group
Group type: EXPERIMENTAL
Intervention: GRIP+TAU
Number of subjects: 46
Study 20817484 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 46
Study 18372267 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen/oxidized regenerated cellulose/antimicrobial matrix
Number of subjects: 49
Study 18372267 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 49
Study 16516824 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg)
Number of subjects: 0
Study 16516824 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (10 mg)
Number of subjects: 0
Study 16516824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16516824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (5 mg, intravenous)
Number of subjects: 0
Study 16516824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (5 mg, intravenous) with neuroleptics
Number of subjects: 0
Study 14618062 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed polarity monophasic shock
Number of subjects: 30
Study 14618062 — intervention group
Group type: COMPARATOR
Intervention: Standard polarity monophasic shock
Number of subjects: 30
Study 14618062 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed polarity biphasic shock
Number of subjects: 30
Study 14618062 — intervention group
Group type: COMPARATOR
Intervention: Standard polarity biphasic shock
Number of subjects: 30
Study 14618062 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed polarity for elevated biphasic DFT (>or=15 J)
Number of subjects: 30
Study 14618062 — intervention group
Group type: COMPARATOR
Intervention: Standard polarity for elevated biphasic DFT (>or=15 J)
Number of subjects: 30
Study 10740150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous felodipine 0.3 mg
Number of subjects: 16
Study 10740150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral felodipine 10 mg
Number of subjects: 16
Study 10740150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2006757 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg/day
Number of subjects: 36
Study 2006757 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 10-40 mg/day
Number of subjects: 36
Study 6128281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin 600 mg daily
Number of subjects: 165
Study 31335590 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (n = 10)
Number of subjects: 34
Study 31335590 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC/COBI/EVG (n = 8)
Number of subjects: 34
Study 31335590 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC/COBI/EVG (n = 7)
Number of subjects: 34
Study 31335590 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (n = 9)
Number of subjects: 34
Study 29414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment costs incurred by patients
Number of subjects: 880
Study 29414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to treatment initiation
Number of subjects: 880
Study 29414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Health systems delay
Number of subjects: 880
Study 29414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher direct OOP medical costs
Number of subjects: 880
Study 29414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with health systems delay
Number of subjects: 880
Study 27168361 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg V116517
Number of subjects: 0
Study 27168361 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg celecoxib
Number of subjects: 0
Study 27168361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat
Number of subjects: 1471
Study 22892409 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program (3 times per week for 6 weeks using rubber exercise bands and Multiaxial Ankle Exerciser)
Number of subjects: 40
Study 22892409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 20572379 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg
Number of subjects: 13
Study 20572379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17969366 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg
Number of subjects: 127
Study 17969366 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 127
Study 16109908 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized arm trainer (AT)
Number of subjects: 44
Study 16109908 — intervention group
Group type: COMPARATOR
Intervention: Electromyography‐initiated electrical stimulation (ES)
Number of subjects: 44
Study 12111113 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (2.3 mg/m(2))
Number of subjects: 11
Study 12111113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous topotecan (1.5 mg/m(2))
Number of subjects: 11
Study 12111113 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl topotecan
Number of subjects: 11
Study 10416208 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 NSAID
Number of subjects: 30
Study 7569824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic swing phase control (Tehlin knee joint)
Number of subjects: 28
Study 7569824 — intervention group
Group type: COMPARATOR
Intervention: Mechanical swing phase control (Otto Bock 3R20)
Number of subjects: 28
Study 2109114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmocare (low carbohydrate formula)
Number of subjects: 10
Study 2109114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure Plus (medium carbohydrate formula)
Number of subjects: 10
Study 2109114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivonex HN (high carbohydrate formula)
Number of subjects: 10
Study 2109114 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Pulmocare to Ensure Plus
Number of subjects: 10
Study 2109114 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Pulmocare to Vivonex HN
Number of subjects: 10
Study 2109114 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Vivonex HN to Pulmocare and Ensure Plus
Number of subjects: 10
Study 6627825 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Number of subjects: 20
Study 6627825 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Number of subjects: 20
Study 31588793 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 60
Study 31588793 — intervention group
Group type: COMPARATOR
Intervention: GL PVP
Number of subjects: 60
Study 31588793 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 60
Study 31588793 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HoLEP, GL PVP, TURP)
Number of subjects: 60
Study 29671128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine succinate 3.2 mg
Number of subjects: 24
Study 29671128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine succinate 6.3 mg
Number of subjects: 24
Study 29671128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine succinate 12.7 mg
Number of subjects: 24
Study 29671128 — intervention group
Group type: COMPARATOR
Intervention: Doxylamine succinate 25 mg oral tablet
Number of subjects: 24
Study 29671128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine (all doses)
Number of subjects: 24
Study 27751707 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone
Number of subjects: 768
Study 27751707 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bortezomib and dexamethasone
Number of subjects: 768
Study 27751707 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone (in patients with at least two previous regimens)
Number of subjects: 768
Study 27751707 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bortezomib and dexamethasone (in patients with at least two previous regimens)
Number of subjects: 768
Study 25199696 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of dexamethasone (2 mL, 8 mg)
Number of subjects: 268